New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
17:37 EDTOGXIOncoGenex CFO Michelle Burris resigns from position, to leave company March 31
OncoGenex disclosed in a regulatory filing that in early January, Scott Cormack, president and CEO, and Michelle Burris, executive VP of operations, CFO, principal accounting officer, treasurer and secretary, disclosed to the company’s board that they have a developing personal relationship with one another that warranted consideration of their reporting relationship and duties. After consideration and discussion by the independent members of the company’s board, as well as consultations with Cormack and Burris, the company’s board determined that it would be advisable for Burris to transfer her executive duties to others and to continue portions of her work in operations as a consultant to the company, reporting directly to the board. On February 1 Burris resigned as the company’s principal accounting officer, CFO, secretary and treasurer. From February 1 to March 31, Burris will continue to serve as the company’s executive VP of operations. Effective March 31, Burris will resign as the company’s executive VP of operations, and the company has agreed to pay all wages, bonuses, vacation, reimbursable expenses and similar payments due to Burris as of such date. On January 31 the company’s board appointed Cormack as the company’s principal financial officer, secretary and treasurer and Susan Wyrick as the company’s principal accounting officer, effective February 1.
News For OGXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
08:21 EDTOGXIOncoGenex Phase 2 Borealis-1 trial resulted in 50% reduction in risk of death
OncoGenex Pharmaceuticals announced results from the randomized, controlled Phase 2 Borealis-1 trial evaluating low and high dose apatorsen in combination with gemcitabine/cisplatin chemotherapy compared to chemotherapy alone in the treatment of metastatic bladder cancer. Overall trial results indicated that the addition of 600mg apatorsen to standard of care chemotherapy showed a 14% reduction in risk of death and a 17% reduction in progressive disease and death when compared to chemotherapy alone. Over one-third of the patients in the trial had lower performance status, as defined by a Karnofsky score of 80 percent or less. These patients derived the greatest benefit from 600mg apatorsen in combination with chemotherapy, resulting in a 50% reduction in risk of death compared to chemotherapy alone. Less benefit was observed in the 1000mg apatorsen arm due to increased adverse events leading to a higher rate of discontinuation of both apatorsen and chemotherapy. Apatorsen 600mg was well tolerated in combination with chemotherapy.
December 16, 2014
06:37 EDTOGXIOncoGenex completes patients enrolment for Rainier clinical trial
Subscribe for More Information
December 12, 2014
16:13 EDTOGXIBiotechnology Value Fund reports 6.43% passive stake in OncoGenex

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use